Welcome to our dedicated page for Glaukos SEC filings (Ticker: GKOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Glaukos Corporation (GKOS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the information. Glaukos is an ophthalmic pharmaceutical and medical technology company focused on therapies for glaucoma, corneal disorders, and retinal diseases, and its filings provide detailed insight into this business.
Through periodic reports such as Forms 10-Q and 10-K, investors can review Glaukos’ net sales, segment performance in glaucoma and corneal health, gross margins, operating expenses, and net income or loss. These filings also describe risk factors relevant to its ophthalmic device and pharmaceutical portfolio, including regulatory requirements, clinical trial processes, reimbursement dynamics, manufacturing considerations, and intellectual property matters referenced in the company’s public communications.
Current reports on Form 8-K capture material events such as quarterly and annual financial results, preliminary net sales updates, and investor presentations. For example, Glaukos has filed 8-Ks to furnish press releases on second and third quarter financial results, preliminary unaudited net sales for a fiscal year, and investor presentation materials. These documents often include or reference revenue guidance ranges and explanations of non-GAAP financial measures and constant currency net sales metrics.
On Stock Titan, AI-generated summaries help explain the key points of lengthy filings, highlighting items such as revenue trends, segment details, and notable risk disclosures without replacing the full text. Real-time updates from EDGAR ensure new Glaukos filings appear promptly, while dedicated sections make it straightforward to locate quarterly reports, annual reports, and current reports tied to material announcements.
For users analyzing GKOS, this page offers a structured view of Glaukos’ SEC reporting history alongside AI insights that clarify complex financial and regulatory information related to its ophthalmic pharmaceutical and medical technology activities.
GLAUKOS Corp chairman and CEO Thomas William Burns reported a routine tax-related share disposition. On March 16, 2,801 shares of common stock were withheld by the company at $98.94 per share to satisfy tax obligations tied to previously granted restricted stock units.
After this withholding, Burns directly holds 242,451 common shares and also has indirect holdings through several family-related trusts. The disclosure notes 64,610 restricted stock units that have not yet vested or been delivered, indicating additional potential future share delivery subject to vesting conditions.
GLAUKOS Corp President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On March 13, 2026, 2,462 shares of common stock at $97.02 per share were withheld by the company to satisfy his tax withholding obligations upon vesting of previously granted restricted stock units.
After this withholding, Gilliam directly holds 88,847 common shares. A footnote also states that his holdings include 56,132 restricted stock units that have not yet vested or been delivered, highlighting a substantial ongoing equity-based compensation position. This event reflects tax settlement mechanics rather than an open-market sale.
Glaukos Corp chief development officer Tomas Navratil reported a tax-related share disposition. On March 13, 2026, 1,074 shares of common stock were withheld at $97.02 per share to satisfy tax withholding obligations tied to vesting restricted stock units.
After this tax-withholding disposition, Navratil directly holds 75,620 shares of common stock, which includes 38,456 restricted stock units that have not yet vested or been delivered.
Glaukos Corp Chairman and CEO Thomas William Burns reported a routine tax-withholding transaction related to equity compensation. On March 13, 2026, 5,212 shares of common stock were withheld by the company at $97.02 per share to satisfy his tax obligations upon vesting and delivery of previously granted restricted stock units.
After this withholding, Burns directly owns 245,252 common shares. He also has indirect ownership through several trusts, including 961,285 shares held through the Burns Family Trust, 238,107 shares through the Burns Annuity Trust, 120,000 shares through the Burns Charitable Remainder Trust, 100,000 shares through the Thomas W. Burns Irrevocable Trust, and 100,000 shares through the Janet M. Burns Irrevocable Trust. Footnotes state that his position also includes 69,929 restricted stock units that have not yet vested or been delivered.
GKOS affiliate filed a Form 144 notice reporting proposed sales of restricted common stock. The notice lists a proposed sale tied to restricted stock vesting of 259 shares with an effective date of 12/27/2024 and 772 shares with an effective date of 01/01/2025.
Glaukos Corp's Chief Development Officer Tomas Navratil reported a small share disposal related to tax withholding. On March 5, 2026, 361 shares of common stock at $112.10 per share were withheld by the company to satisfy his tax obligations upon vesting of previously granted restricted stock units.
After this tax-withholding disposition, Navratil directly holds 76,694 shares of common stock, which includes 41,561 restricted stock units that have not yet vested or been delivered to him.
Glaukos Corp (GKOS) Chairman & CEO Thomas William Burns reported a tax-related share disposition on March 5, 2026. The company withheld 1,098 shares of common stock at $112.10 per share to cover his tax obligations when previously granted restricted stock units vested.
After this withholding, he directly owns 250,464 common shares, which includes 79,828 restricted stock units that have not yet vested or been delivered. He also reports indirect ownership through several Burns family and charitable trusts, including the Burns Family Trust, Burns Annuity Trust, Burns Charitable Remainder Trust, and two irrevocable trusts, each with disclosed share balances as of the same date.
Glaukos Corporation furnished a new Investor Presentation as Exhibit 99.1 to a current report. The company states it may use this March 2026 presentation from time to time in meetings with investors and other stakeholders, and it will be available on the investor page of its website.
The company clarifies that the Investor Presentation and related disclosure under Item 7.01 are being provided under Regulation FD and are not deemed filed under Section 18 of the Exchange Act or incorporated into other securities law filings unless specifically referenced.
Glaukos Corp chairman and CEO Thomas William Burns reported a tax-withholding share disposition related to restricted stock units. On February 24, 2026, 4,059 shares of common stock were withheld by Glaukos at $119.17 per share to satisfy his tax obligations upon RSU vesting.
After this transaction, Burns directly owns 251,562 shares of Glaukos common stock, which the footnotes state include 81,912 unvested restricted stock units. He also reports additional indirect ownership through multiple Burns family-related trusts, each holding separate blocks of Glaukos shares.